Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.90) EPS for the quarter, beating analysts’ consensus estimates of ($1.19) by $0.29, Yahoo Finance reports.
Corbus Pharmaceuticals Price Performance
NASDAQ CRBP traded down $5.23 during trading on Wednesday, reaching $47.71. The company’s stock had a trading volume of 249,407 shares, compared to its average volume of 544,288. The stock has a market capitalization of $510.02 million, a PE ratio of -6.96 and a beta of 2.59. The firm has a fifty day moving average of $50.60 and a 200 day moving average of $40.18. Corbus Pharmaceuticals has a one year low of $3.03 and a one year high of $61.90.
Insider Activity
In other news, CEO Yuval Cohen sold 11,103 shares of the stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $46.02, for a total transaction of $510,960.06. Following the transaction, the chief executive officer now directly owns 84,400 shares in the company, valued at approximately $3,884,088. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Sean F. Moran sold 9,355 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $49.87, for a total transaction of $466,533.85. Following the transaction, the chief financial officer now directly owns 48,605 shares in the company, valued at approximately $2,423,931.35. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Yuval Cohen sold 11,103 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $46.02, for a total value of $510,960.06. Following the transaction, the chief executive officer now owns 84,400 shares in the company, valued at $3,884,088. The disclosure for this sale can be found here. In the last three months, insiders have sold 51,733 shares of company stock worth $2,530,799. 4.00% of the stock is currently owned by insiders.
Analyst Ratings Changes
Check Out Our Latest Stock Report on Corbus Pharmaceuticals
Corbus Pharmaceuticals Company Profile
Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.
Read More
- Five stocks we like better than Corbus Pharmaceuticals
- Transportation Stocks Investing
- What Are Bonds? A High-Level Overview
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Super Micro Stock Drops Sharply After Earnings on Margin Concerns
- How to Use Stock Screeners to Find Stocks
- Lyft’s First-Ever Profit, but the Outlook Is a Speed Bump
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.